

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Rozenman Mary M.</u> (Last) (First) (Middle) AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 (Street) BRISBANE CA 94005-1884 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Aimmune Therapeutics, Inc. [AIMT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) See Remarks
	3. Date of Earliest Transaction (Month/Day/Year) <u>12/26/2017</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.0001 par value	12/26/2017		M		75,010	A	\$3.022	75,139	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		11,000	D	\$38.8263 ⁽²⁾	64,139	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		1,500	D	\$39.252 ⁽³⁾	62,639	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		10,700	D	\$38.8151 ⁽²⁾	51,939	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		1,800	D	\$39.225 ⁽⁴⁾	50,139	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		11,000	D	\$38.8286 ⁽⁵⁾	39,139	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		1,500	D	\$39.25 ⁽⁶⁾	37,639	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		11,000	D	\$38.8221 ⁽⁷⁾	26,639	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		1,500	D	\$39.2313 ⁽⁸⁾	25,139	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		4,310	D	\$38.8026 ⁽⁹⁾	20,829	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		700	D	\$39.2557 ⁽¹⁰⁾	20,129	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		8,800	D	\$38.8253 ⁽¹¹⁾	11,329	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		1,200	D	\$39.2783 ⁽¹²⁾	10,129	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		6,400	D	\$38.7263 ⁽¹³⁾	3,729	D	
Common Stock, \$0.0001 par value	12/26/2017		S ⁽¹⁾		3,600	D	\$39.1526 ⁽¹⁴⁾	129	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V		Date Exercisable	Expiration Date						Amount or Number of Shares
Stock Option (right to buy)	\$3.022	12/26/2017		M		75,010	(15)	04/17/2025	Common Stock	75,010	\$0.00	120,426	D	

Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
2. The transaction was executed in multiple trades in prices ranging from \$38.13 to \$39.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
3. The transaction was executed in multiple trades in prices ranging from \$39.14 to \$39.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
4. The transaction was executed in multiple trades in prices ranging from \$39.14 to \$39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
5. The transaction was executed in multiple trades in prices ranging from \$38.14 to \$39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
6. The transaction was executed in multiple trades in prices ranging from \$39.15 to \$39.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
7. The transaction was executed in multiple trades in prices ranging from \$38.12 to \$39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
8. The transaction was executed in multiple trades in prices ranging from \$39.13 to \$39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
9. The transaction was executed in multiple trades in prices ranging from \$38.14 to \$39.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
10. The transaction was executed in multiple trades in prices ranging from \$39.15 to \$39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
11. The transaction was executed in multiple trades in prices ranging from \$38.15 to \$39.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
12. The transaction was executed in multiple trades in prices ranging from \$39.16 to \$39.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
13. The transaction was executed in multiple trades in prices ranging from \$38.06 to \$39.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
14. The transaction was executed in multiple trades in prices ranging from \$39.07 to \$39.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
15. The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from February 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

Senior VP, Corporate Development and Strategy

/s/ Douglas T. Sheehy, as
Attorney-in-Fact for Mary M. Rozenman 12/28/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.